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Consider this option for  
heavy menstrual bleeding
Women who fail to respond to—or are unable to 
tolerate—other treatments for heavy menstrual blood 
loss now have another choice.
Practice changer
Offer tranexamic acid to patients with heavy 
menstrual bleeding. The extended-release 
formulation is effective and well tolerated.1 
Strength of recommendation
a: Based on 1 good-quality randomized con-
trolled trial (RCT).
Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for 
heavy menstrual bleeding: a randomized controlled trial. Obstet 
Gynecol. 2010;116:865-875. 
illustrative case
a 32-year-old woman comes to your office 
complaining of heavy, but regular, menstrual 
bleeding, accompanied by clots and heavy 
cramping that often leave her drained and 
unable to work. She has taken oral contra-
ceptives in the past, but they caused nausea, 
and nonsteroidal anti-inflammatory drugs 
(nSaiDs) did not provide adequate symptom 
relief. 
a pelvic ultrasound shows that the pa-
tient has normal endometrial thickness and 
no fibroids. aside from surgical intervention 
or the placement of a hormonal intrauterine 
device (iuD), what can you offer her?
Heavy menstrual bleeding is a fre-quent problem, common enough to cause an estimated 10% to 30% 
of women of reproductive age to seek treat-
ment.2-4 Often the bleeding is severe enough 
to adversely affect the patient’s social, physi-
cal, and emotional well-being. 
Adverse effects, variable efficacy  
limit use of other treatments
Quantitatively defined as blood loss ≥80 mL 
per cycle, heavy menstrual bleeding can also 
be diagnosed based on a patient’s perception 
of menstrual blood loss and its effect on her 
daily life.5,6 NSAIDs, hormonal medications, 
the placement of a hormonal IUD, and surgi-
cal procedures are all treatment options, but 
potential adverse effects, contraindications, 
personal preference, and variable efficacy 
can limit their use.7
the fibrinolysis-blood loss link 
Fibrinolytic activity in menstrual blood, 
leading to increasing blood loss, has prompt-
ed the evaluation of hemostatic agents as po-
tential therapeutic options.8 Oral tranexamic 
acid decreases fibrinolysis, thereby reducing 
menstrual blood loss;9 however, gastrointes-
tinal (GI) side effects limit the usefulness of 
immediate-release tranexamic acid.9,10 
This formulation of tranexamic acid 
has been used in Europe for heavy men-
strual bleeding. A Cochrane review pub-
lished in 2000 included 4 studies that 
compared immediate-release tranexam-
ic acid therapy with placebo. The meta- 
analysis found a significant reduction in 
mean blood loss compared with placebo 
(weighted mean difference [WMD]=-94.0 mL; 
95% confidence interval [CI], -151.4 to -36.5) 
and a significant change in mean reduc-
tion of blood loss (WMD=-110.2 mL; 95% CI, 
-146.5 to -73.8) compared with baseline in 
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the treatment group. However, only one of the 
studies measured perceived improvement in 
monthly menstrual blood loss, and its sample 
size was inadequate to provide a precise esti-
mate of the effect (relative risk [RR] 2.5; 95% 
CI, 0.9-7.3).11
z An extended-release option. Oral 
extended-release (ER) tranexamic acid 
(Lysteda), approved by the US Food and Drug 
Administration in 2009,12 reduces blood loss 
with fewer GI effects than immediate-release 
tranexamic acid. In the RCT detailed below, 
Lukes et al assessed the efficacy and safety of 
this new formulation. 
study summary
ER formulation reduces blood loss, 
boosts quality of life
The researchers conducted a multicenter, 
randomized, double-blind placebo-con-
trolled study comparing the effect of ER 
tranexamic acid on reduction of menstrual 
blood flow compared with placebo.1 Reduc-
tion in menstrual blood loss >50 mL and a 
reduction in menstrual blood loss ≥36 mL 
(an amount previously established to be per-
ceived as meaningful to women) were related 
primary outcomes. Improvements in limita-
tions in social or leisure and physical activi-
ties and in self-perceived menstrual blood 
loss were secondary outcomes.
Study participants were women ages 
18 to 49 years who had heavy menstrual 
bleeding, a normal pelvic exam, and a nor-
mal transvaginal ultrasound; current use of 
a nonhormonal birth control method was 
also required. Women with fibroids were not 
excluded unless surgery was planned. Exclu-
sion criteria included significant coagula-
tion issues, endocrinopathy, ocular disease, 
pregnancy or lactation, endometrial abnor-
malities, cervical cancer, anovulatory dys-
functional uterine bleeding, metrorrhagia, 
menometrorrhagia, and polymenorrhea. 
Participants were randomized to receive 
either tranexamic acid 1.3 g by mouth 3 times 
a day for 5 days per menstrual cycle, begin-
ning with the onset of heavy bleeding, or a 
matched placebo. The use of anticoagulants 
or NSAIDs during the menstrual period was 
not permitted. 
Heavy bleeding was defined as ≥60 mL of 
blood loss in one measured cycle and an aver-
age ≥80 mL of blood loss over 2 measured 
cycles. 
Mean reduction in blood loss per cycle 
over 6 cycles was 70 mL (a 40.4% reduction) in 
the active treatment group vs 13 mL (an 8.2% 
reduction) in the placebo group (P<.001). 
The proportion of women with a ≥50% reduc-
tion from baseline in blood loss was greater 
in the tranexamic acid group compared with 
the placebo group (35% vs 7%; P<.001), yield-
ing a number needed to treat of 4. The mean 
reduction in perceived blood loss was also 
greater in the treatment group, but the differ-
ence was not statistically significant. 
The researchers used a validated men-
strual quality-of-life scale that measured 
social and physical quality of life using a 
5-point Likert scale. Women treated with 
tranexamic acid had a mean reduction of 
0.89 points from baseline on the social and 
leisure activity question, compared with a 
mean reduction of 0.38 points for those in 
the placebo group. On the physical activity 
question, those in the tranexamic acid group 
had a mean reduction of 0.90 points from 
baseline, vs a mean decline of 0.35 points in 
the placebo group.
These findings indicate that the women 
who received tranexamic acid experienced 
significantly fewer limitations in social and 
physical activities. Responses to a question 
about limitations in work activities showed 
that the treatment group had significant im-
provements there, as well. The ER form of 
tranexamic acid used in the study was well 
tolerated, with no significant differences in 
adverse effects between the intervention and 
control groups. 
What’s neW
Women with heavy menstrual bleeding 
have a new option
The ER formulation of tranexamic acid used 
in the study does not appear to have the GI 
side effects associated with the immediate-
release formula. 
Tranexamic acid is taken only during the 
menstrual cycle and does not interfere with 
ovulation. Thus, it can be used by women 
Extended-release 
tranexamic 
acid is better 
tolerated than 
the immediate-
release 
formulation, 
with fewer Gi 
adverse effects.
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Women who 
took tranexamic 
acid were  
5 times more 
likely to have a 
≥50% reduction 
in blood loss 
from baseline 
compared with 
those receiving 
placebo.
who desire fertility but are troubled by heavy 
bleeding.
caveats
Questions about related conditions,  
use with hormones remain
The study included women with regular 
heavy menstrual periods (menorrhagia) and 
therefore may not be applicable to those with 
irregular heavy periods or anovulatory, dys-
functional uterine bleeding. In clinical prac-
tice, these conditions may overlap, but the 
safety and efficacy of tranexamic acid in such 
cases is unclear. 
Another caveat, at least theoretically, is 
that research to date has neither identified 
nor excluded the possibility that tranexam-
ic acid with concomitant use of hormonal 
agents might increase the risk of thrombotic 
events.13 This risk is low based on evidence 
to date, but the theoretical uncertainty leads 
us to be cautious about the combination of 
tranexamic acid and hormonal therapy for 
long-term use. 
Xanodyne Pharmaceuticals (which 
manufactured Lysteda) and Ferring Phar-
maceuticals (its current owner) were ma-
jor sponsors of this study. While we cannot 
recognize any source of bias as a result of 
sponsorship, the independence of the in-
vestigators in publishing the findings was 
not clearly stated, so it is possible that future 
independent studies would contradict these 
findings. 
challenges to imPlementation
the treatment is costly 
Lysteda is expensive, costing about $170 for 
30 tablets of 650 mg each.14 Cost aside, ER 
tranexamic acid appears to be safe, with no 
major barriers to its use.                  JFP
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